| Literature DB >> 24317468 |
Wei Jiang1, Panpan Ye, Chen-Tung Arthur Chen, Kuiwu Wang, Pengyuan Liu, Shan He, Xiaodan Wu, Lishe Gan, Ying Ye, Bin Wu.
Abstract
Two novel cyclodepsipeptides containing an unusual anthranilic acid dimer and a D-phenyllactic acid residues, clavatustides A and B, were identified from cultured mycelia and broth of Aspergillus clavatus C2WU isolated from Xenograpsus testudinatus, which lives at extreme, toxic habitat around the sulphur-rich hydrothermal vents in Taiwan Kueishantao. This is the first example of cyclopeptides containing an anthranilic acid dimer in natural products, and the first report of microbial secondary metabolites from the hydrothermal vent crab. Clavatustides A and B suppressed the proliferation of hepatocellular carcinoma (HCC) cell lines (HepG2, SMMC-7721 and Bel-7402) in a dose-dependent manner, and induced an accumulation of HepG2 cells in G1 phase and reduction of cells in S phase.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24317468 PMCID: PMC3877885 DOI: 10.3390/md11124761
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Chart 1Structures of compounds 1 and 2.
Figure 1Key 1H 1H COSY and HMBC correlations of compound 1.
Figure 2CID illustration of compound 1.
NMR Data (500 MHz) for Compound 1 and 2 in CDCl3.
| Position | 1 | 2 | ||
|---|---|---|---|---|
| δC | δH | δC | δH | |
| 1 | 169.6, C | 169.8, C | ||
| 2 | 71.7, CH | 5.49, dd (8.3, 6.3) | 71.5, CH | 5.51 t (7.5) |
| 3 | 37.6, CH2 | 3.46, dd (13.7, 8.3); 3.25, overlap | 37.2, CH2 | 3.39, dd (13.6, 7.5); 3.25, (13.6, 7.5) |
| 4 | 135.9, C | 135.5, C | ||
| 5/9 | 129.7, CH | 7.34, overlap | 129.6, CH | 7.31, overlap |
| 6/8 | 128.7, CH | 7.37, overlap | 128.7, CH | 7.34, overlap |
| 7 | 127.3, CH | 7.34, overlap | 127.4, CH | 7.31, overlap |
| anthranilic acid I | ||||
| 10 | 167.1, C | 167.5, C | ||
| 11 | 127.8, C | 127.4 | ||
| 12 | 129.7, CH | 7.63, d (7.6) | 129.6, CH | 7.62, d (7.8) |
| 13 | 126.6, CH | 7.30, overlap | 126.5, CH | 7.30, overlap |
| 14 | 132.5, CH | 7.50, t (7.6) | 132.7, CH | 7.44, t (7.8) |
| 15 | 125.8, CH | 7.22, d (7.6) | 126.1, CH | 7.19, d (7.8) |
| 16 | 134.4, C | 134.8, C | ||
| NH | 8.07, s | 8.58, s | ||
| anthranilic acid II | ||||
| 17 | 167.3, C | 167.4, C | ||
| 18 | 123.0, C | 123.1, C | ||
| 19 | 126.2, CH | 7.58, d (7.6) | 126.5, CH | 7.56, d (7.8) |
| 20 | 123.1, CH | 7.10, t (7.6) | 123.2, CH | 7.03, t (7.8) |
| 21 | 132.3, CH | 7.46, t (7.6) | 132.2, CH | 7.40, t (7.8) |
| 22 | 122.0, CH | 8.57, d (7.6) | 121.9, CH | 8.48, d (7.8) |
| 23 | 138.2, C | 137.9, C | ||
| NH | 10.23, s | 10.17, s | ||
| glycine | ||||
| 24 | 168.1, C | 167.5, C | ||
| 25 | 51.7, CH2 | 5.24, d (15.2); 3.29, d (15.2) | 54.1, CH2 | 5.25, d (14.8); 3.10 d (14.8) |
| 26 | 43.3, CH2 | 3.95, m; 3.27, m | 35.9, CH3 | 3.01, s |
| CH3 | 13.7, CH3 | 1.02, t, (7.2) | ||
, Recorded at 125 MHz; , Multiplicities inferred from DEPT and HSQC experiments; , Recorded at 500 MHz; , Interchangeable.
Figure 3The suppression of cell proliferation of clavatustide A (A) and clavatustide B (B) in a dose-dependent manner.
Figure 4The suppression of cell proliferation of clavatustide A and clavatustide B in L02 (A) and HepG2 (B) was in a time dependent manner. * P < 0.05 if treatment group vs. control group. L02, liver cells; HepG2, SMMC-7721 and Bel-7402, human hepatocellular carcinoma (HCC) cell lines.
G1 arrest and S phase reduction of clavatustides A and B on HepG2 cells.
| G1 Phase | S Phase | G2 Phase | |
|---|---|---|---|
| Clavatustide A | 59.17% | 17.73% | 23.10% |
| Clavatustide B | 67.57% | 11.92% | 20.52% |
| Blank control | 41.03% | 19.49% | 39.48% |
Figure 5The comparison of cell cycle (A), cell migration (B) and invasion (C) between HepG2 cells treated with clavatustide A/clavatustide B and the blank control. A: Clavatustide A/clavatustide B treated cells showed significantly accumulation in G1 phase and reduction of cells in S phase, compared with control group (P < 0.05). B and C: The counted migrated/invaded cell numbers did not differ significantly between treated groups and control group.